Pr VIAGRA*
... Geriatrics (> 65 years of age): Healthy elderly volunteers had a reduced clearance of sildenafil, with free plasma concentrations approximately 40% greater than those seen in younger volunteers (18 to 45 years). Since higher plasma levels may increase both the pharmacological action and incidence of ...
... Geriatrics (> 65 years of age): Healthy elderly volunteers had a reduced clearance of sildenafil, with free plasma concentrations approximately 40% greater than those seen in younger volunteers (18 to 45 years). Since higher plasma levels may increase both the pharmacological action and incidence of ...
HIGHLIGHTS OF PRESCRIBING INFORMATION
... discontinued prior to starting therapy with VIEKIRA PAK [see Contraindications (4)]. Alternative methods of contraception (e.g, progestin only contraception or non-hormonal methods) are recommended during VIEKIRA PAK therapy. Ethinyl estradiol-containing medications can be restarted approximately 2 ...
... discontinued prior to starting therapy with VIEKIRA PAK [see Contraindications (4)]. Alternative methods of contraception (e.g, progestin only contraception or non-hormonal methods) are recommended during VIEKIRA PAK therapy. Ethinyl estradiol-containing medications can be restarted approximately 2 ...
methotrexate - Cancer Care Ontario
... Methotrexate is contraindicated in patients with a known hypersensitivity to methotrexate or its excipients. Methotrexate should be used with extreme caution in patients with a history of peptic ulceration or ulcerative colitis and in patients with poor performance status, with active infection, imp ...
... Methotrexate is contraindicated in patients with a known hypersensitivity to methotrexate or its excipients. Methotrexate should be used with extreme caution in patients with a history of peptic ulceration or ulcerative colitis and in patients with poor performance status, with active infection, imp ...
Product Monograph ZANTAC
... Rare cases of hypersensitivity reactions (including chest pain, bronchospasm, fever, rash, eosinophilia, anaphylaxis, urticaria, angioneurotic edema, hypotension) and small increases in serum creatinine have occasionally occurred after a single dose. Acute pancreatitis and reversible impotence has b ...
... Rare cases of hypersensitivity reactions (including chest pain, bronchospasm, fever, rash, eosinophilia, anaphylaxis, urticaria, angioneurotic edema, hypotension) and small increases in serum creatinine have occasionally occurred after a single dose. Acute pancreatitis and reversible impotence has b ...
Product Monograph ZANTAC Histamine H
... concentrations (300 to 550 ng/mL) occurred after 1 to 3 hours. Two distinct peaks or a plateau in the absorption phase result from reabsorption of drug excreted into the intestine. These plasma concentrations are not significantly influenced by the presence of food in the stomach at the time of the ...
... concentrations (300 to 550 ng/mL) occurred after 1 to 3 hours. Two distinct peaks or a plateau in the absorption phase result from reabsorption of drug excreted into the intestine. These plasma concentrations are not significantly influenced by the presence of food in the stomach at the time of the ...
PrZOFRAN® Tablets, Oral Solution and Injection PrZOFRAN® ODT
... There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ZOFRAN was significantly reduced and the serum half-life significantly prolonged in subjects with severe impairment of hepatic function. In patients with moderate or severe impairment of hep ...
... There is no experience in patients who are clinically jaundiced. The clearance of an 8 mg intravenous dose of ZOFRAN was significantly reduced and the serum half-life significantly prolonged in subjects with severe impairment of hepatic function. In patients with moderate or severe impairment of hep ...
Azithromycin for Injection, USP
... In vitro and in vivo studies to assess the metabolism of azithromycin have not been performed. Elimination Plasma concentrations of azithromycin following single 500-mg oral and I.V. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination h ...
... In vitro and in vivo studies to assess the metabolism of azithromycin have not been performed. Elimination Plasma concentrations of azithromycin following single 500-mg oral and I.V. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination h ...
Sootheze Six Plus Paracetamol 250mg/5ml Oral Suspension
... Analgesics containing paracetamol have been available in the UK for much more than ten years. Their use is well established with recognised efficacy and acceptable safety. The application was submitted under the legal basis of a bibliographic application. In this regard, the applicant has submitted ...
... Analgesics containing paracetamol have been available in the UK for much more than ten years. Their use is well established with recognised efficacy and acceptable safety. The application was submitted under the legal basis of a bibliographic application. In this regard, the applicant has submitted ...
PrZOFRAN® Tablets, Oral Solution and Injection PrZOFRAN® ODT
... Specific studies have shown that there are no pharmacokinetic interactions when ondansetron is administered with alcohol, temazepam, furosemide, tramadol or propofol. Ondansetron is metabolised by multiple hepatic cytochrome P450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Despite the multiplicity of metabo ...
... Specific studies have shown that there are no pharmacokinetic interactions when ondansetron is administered with alcohol, temazepam, furosemide, tramadol or propofol. Ondansetron is metabolised by multiple hepatic cytochrome P450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Despite the multiplicity of metabo ...
PRODUCT INFORMATION METHADONE SYRUP
... disturbances. Abstinence syndrome may not occur in the neonate for some days after birth. Therefore, in addition to initial monitoring of respiratory depression, neonates should undergo prolonged monitoring for signs and symptoms of withdrawal. Infants born to mothers on methadone maintenance have b ...
... disturbances. Abstinence syndrome may not occur in the neonate for some days after birth. Therefore, in addition to initial monitoring of respiratory depression, neonates should undergo prolonged monitoring for signs and symptoms of withdrawal. Infants born to mothers on methadone maintenance have b ...
New Zealand Datasheet Name of Medicine Presentation CIPROFLOXACIN
... animal experimental data together with limited human data. Two month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician is referred to national and /or international c ...
... animal experimental data together with limited human data. Two month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician is referred to national and /or international c ...
... aspartate 113, serine 204, serine 207 and phenylalanine 290, known from molecular biology studies on genetically engineered recombinant point-mutated receptors to be crucial for ligand binding [21–24]. The binding of adrenaline to key amino acid residues in the active site of the beta2-adrenoceptor ...
Tramadol - Medsafe
... tachycardia" and "nausea/urge to vomit/vomiting" was significantly increased with rapid intravenous administration and also tended to be dose dependent. Drug abuse and dependence Although tramadol can produce drug dependence of the µ-opioid type (like codeine or dextropropoxyphene) and potentially m ...
... tachycardia" and "nausea/urge to vomit/vomiting" was significantly increased with rapid intravenous administration and also tended to be dose dependent. Drug abuse and dependence Although tramadol can produce drug dependence of the µ-opioid type (like codeine or dextropropoxyphene) and potentially m ...
ARE STATINS NEPHROPROTECTIVE?:A DOSE DEPENDENT STUDY IN ALBINO RATS Research Article
... Purpose:The purpose of the study was to evaluate the dose dependent effects of atorvastatin against vancomycin induced renal damage. Methods:Nephrotoxicity was induced by vancomycin administration at a dose of 200mg/kg twice daily for 7 days. Nephrotoxicity was determined by carrying out renal funct ...
... Purpose:The purpose of the study was to evaluate the dose dependent effects of atorvastatin against vancomycin induced renal damage. Methods:Nephrotoxicity was induced by vancomycin administration at a dose of 200mg/kg twice daily for 7 days. Nephrotoxicity was determined by carrying out renal funct ...
Hemoperfusion - Hyderabad Nephrology forum
... – can remove only substances that are highly diffusable, non protein bound and with small and middle-molecular weight. ...
... – can remove only substances that are highly diffusable, non protein bound and with small and middle-molecular weight. ...
LOSARTAN POTASSIUM AMLODIPINE CAMSYLATE
... Plasma concentrations of losartan and its active metabolite and the antihypertensive effect of losartan increase with increasing dose. Since losartan and its active metabolite are both angiotensin II receptor antagonists, they both contribute to the antihypertensive effect. In a single-dose study in ...
... Plasma concentrations of losartan and its active metabolite and the antihypertensive effect of losartan increase with increasing dose. Since losartan and its active metabolite are both angiotensin II receptor antagonists, they both contribute to the antihypertensive effect. In a single-dose study in ...
Atrial fibrillation: the management of atrial fibrillation
... This guideline offers best practice advice on the care of adults (aged 18 and over) with suspected or diagnosed atrial fibrillation. Patients and healthcare professionals have rights and responsibilities as set out in the NHS Constitution for England – all NICE guidance is written to reflect these. ...
... This guideline offers best practice advice on the care of adults (aged 18 and over) with suspected or diagnosed atrial fibrillation. Patients and healthcare professionals have rights and responsibilities as set out in the NHS Constitution for England – all NICE guidance is written to reflect these. ...
product monograph
... ASA or dual antiplatelet therapy with either ELIQUIS or warfarin increases the risk of major bleeding in patients with atrial fibrillation. Other platelet aggregation inhibitors such as prasugrel and ticagrelor, have not been studied with ELIQUIS in any patient population, and are not recommended as ...
... ASA or dual antiplatelet therapy with either ELIQUIS or warfarin increases the risk of major bleeding in patients with atrial fibrillation. Other platelet aggregation inhibitors such as prasugrel and ticagrelor, have not been studied with ELIQUIS in any patient population, and are not recommended as ...
Reyataz ® (atazanavir) - Bristol
... between protease inhibitor therapy and these events has not been established. Hepatic/Biliary Hepatic Impairment and Toxicity: REYATAZ is principally metabolized by the liver; caution should be exercised when administering this drug to patients with hepatic impairment because atazanavir concentratio ...
... between protease inhibitor therapy and these events has not been established. Hepatic/Biliary Hepatic Impairment and Toxicity: REYATAZ is principally metabolized by the liver; caution should be exercised when administering this drug to patients with hepatic impairment because atazanavir concentratio ...
Recommendations for Management of Clinically Significant Drug
... result in altered absorption, distribution, metabolism, or excretion of a medication. A pharmacodynamic DDI occurs when 1 medication modifies the pharmacological effect of another in an additive, a synergistic, or an antagonistic fashion. It is estimated that ≈2.8% of hospital admissions occur as a ...
... result in altered absorption, distribution, metabolism, or excretion of a medication. A pharmacodynamic DDI occurs when 1 medication modifies the pharmacological effect of another in an additive, a synergistic, or an antagonistic fashion. It is estimated that ≈2.8% of hospital admissions occur as a ...
Xtram
... "nausea/urge to vomit/vomiting" can be increased with rapid intravenous administration and also tends to be dose dependent. No tests of significance have been performed. Drug abuse and dependence Although Tramadol can produce drug dependence of the µ-opioid type (like codeine or dextropropoxyphene) ...
... "nausea/urge to vomit/vomiting" can be increased with rapid intravenous administration and also tends to be dose dependent. No tests of significance have been performed. Drug abuse and dependence Although Tramadol can produce drug dependence of the µ-opioid type (like codeine or dextropropoxyphene) ...
Platelet inhibitory activity and pharmacokinetics of prasugrel
... ADP receptor have also provided improved clinical outcomes in patients with non ST-elevation ACS and those undergoing percutaneous coronary intervention (PCI) [4–7]. Ticlopidine and clopidogrel are thienopyridine prodrugs which following oral administration are metabolized to an active sulfhydryl fo ...
... ADP receptor have also provided improved clinical outcomes in patients with non ST-elevation ACS and those undergoing percutaneous coronary intervention (PCI) [4–7]. Ticlopidine and clopidogrel are thienopyridine prodrugs which following oral administration are metabolized to an active sulfhydryl fo ...
Chloral Hydrate Mixture 1g/10mL
... thereby increase the potential for excessive CNS depression, predispose neonates to conjugated and non-conjugated hyperbilirubinaemia, decrease albumin binding of bilirubin, and contribute to metabolic acidosis. Chloral Hydrate Mixture is not recommended in infants and children when repetitive dosi ...
... thereby increase the potential for excessive CNS depression, predispose neonates to conjugated and non-conjugated hyperbilirubinaemia, decrease albumin binding of bilirubin, and contribute to metabolic acidosis. Chloral Hydrate Mixture is not recommended in infants and children when repetitive dosi ...
Atrial fibrillation: management
... concurrent medication, for example concomitant use of aspirin or a non-steroidal anti-inflammatory drug (NSAID) harmful alcohol consumption. [new 2014] ...
... concurrent medication, for example concomitant use of aspirin or a non-steroidal anti-inflammatory drug (NSAID) harmful alcohol consumption. [new 2014] ...
PRODUCT MONOGRAPH PrZOLOFT® (sertraline hydrochloride) 25
... concentration (Cmax) of sertraline is 0.19 µg/mL occurring between 6 to 8 hours post-dose. The area under the plasma concentration time curve is 2.8 mg hr/l. For desmethylsertraline, Cmax is 0.14 µg/mL, the half-life 65 hours and the area under the curve 2.3 mg hr/l. Following single or multiple ora ...
... concentration (Cmax) of sertraline is 0.19 µg/mL occurring between 6 to 8 hours post-dose. The area under the plasma concentration time curve is 2.8 mg hr/l. For desmethylsertraline, Cmax is 0.14 µg/mL, the half-life 65 hours and the area under the curve 2.3 mg hr/l. Following single or multiple ora ...
Discovery and development of direct thrombin inhibitors
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a more safer anticoagulant.